Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Kongtim P, et al. Among authors: hosing cm. Leukemia. 2017 Jul;31(7):1654-1657. doi: 10.1038/leu.2017.118. Epub 2017 Apr 12. Leukemia. 2017. PMID: 28400618 Free PMC article. No abstract available.
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Shah N, et al. Among authors: hosing cm. Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27. Leukemia. 2015. PMID: 25721897 Free PMC article. Clinical Trial. No abstract available.
Umbilical cord blood graft engineering: challenges and opportunities.
Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Thompson PA, et al. Among authors: hosing cm. Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S55-62. doi: 10.1038/bmt.2015.97. Bone Marrow Transplant. 2015. PMID: 26039209 Review.
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities.
Popat UR, Pasvolsky O, Bassett R Jr, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Popat UR, et al. Among authors: hosing cm. Blood Adv. 2023 Oct 24;7(20):6196-6205. doi: 10.1182/bloodadvances.2023010850. Blood Adv. 2023. PMID: 37611156 Free PMC article. Clinical Trial.
HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection.
Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. Mehta RS, et al. Among authors: hosing cm. Transplant Cell Ther. 2023 Mar;29(3):189-198. doi: 10.1016/j.jtct.2022.11.027. Epub 2022 Dec 5. Transplant Cell Ther. 2023. PMID: 36470579 Free PMC article.
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Singh H, et al. Among authors: hosing cm. Front Immunol. 2022 Nov 10;13:1032397. doi: 10.3389/fimmu.2022.1032397. eCollection 2022. Front Immunol. 2022. PMID: 36439104 Free PMC article. Clinical Trial.
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation.
Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mehta RS, et al. Among authors: hosing cm. Transplant Cell Ther. 2022 Oct;28(10):695.e1-695.e10. doi: 10.1016/j.jtct.2022.07.021. Epub 2022 Jul 25. Transplant Cell Ther. 2022. PMID: 35902049 Free article.
A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study.
Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. Popat UR, et al. Among authors: hosing cm. Haematologica. 2022 Oct 1;107(10):2496-2500. doi: 10.3324/haematol.2022.280778. Haematologica. 2022. PMID: 35770531 Free PMC article. Clinical Trial. No abstract available.
54 results